Actinogen Medical Limited has released a press release.
XanADu Interim Analysis-Continuation Without Change
Filed with ASX ·
6ix hasn’t read this filing yet.
Actinogen Medical Limited on 6ix
Earlier from Actinogen Medical
- March 2018 Quarterly Report
- Mid-Way Point Reached in Landmark Alzheimers Trial - XanADu
- Strong Recruitment Progress in Alzheimers Trial
- New Data Supports Cortisol Hypothesis
- December 2017 Quarterly Report
Later from Actinogen Medical
- $15m Placement Completed-Including US Cornerstone Investor
- Share Purchase Plan
- New Study Sites Added to Accelarate Patient Recruitment
- Placement under Share Purchase Plan Shortfall
- June 2018 Quarterly Report
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical